NVIV News and Press, InVivo Therapeutics Holdings Corp. From 01/28/19

Gainers:  Helios and Matheson Analytics (NASDAQ: HMNY ) +49% . Cool Holdings (NASDAQ: AWSM ) +20% . Fortress Biotech (NASDAQ: FBIO ) +19% . Azure Power Global (NYSE: AZRE ) +18% . MYnd Analytics (NASDAQ: MYND ) +18% . Versum Materials (NYSE: VSM ) +16% . Reebonz Holding ( RBZ ) ...

InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announces the appointment of Richard Christopher as its Chief Financial Officer and Treasurer, effective Ja...

InVivo Therapeutics (NASDAQ: NVIV ) has entered into a joint research agreement with Q Therapeutics, a privately held developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury. More news on: InVivo Therapeutics Holdings Corp, Healthcare stocks news, S...

- Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal Scaffold™ with stem cells - InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries ...

- Supports INSPIRE clinical investigation of the Neuro-Spinal Scaffold - InVivo Therapeutics Holdings Corp. (Nasdaq:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries (SCIs), today announced the publication o...

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New Y...